拜耳集团Bayer AG (BAYZF) 2016年年度报告「OTC」.pdf

1、Annual ReportAugmented Version2016ZonesColorAcresZone 11.6 6.9 Zone 21.2 Zone 3Show true colorFiscal 2016:Another record year for Bayer good progress with the acquisition of Monsanto Group sales 46.8 billion(Fx&portfolio adj.+3.5%)Substantial sales and earnings increases at Pharmaceuticals Consumer

2、Health grows with competition Crop Science successful in a difficult market environment EBITDA before special items 11.3 billion(+10.2%)Net income 4.5 billion(+10.2%)Core earnings per share 7.32(+7.3%)Operating cash flow 8.3 billion(+20.8%)Forecast for 2017:further growth in sales and earnings Cover

3、 picture:The digitization of farming aims to support the efficient and sustainable use of resources.Our cover shows Charles Godoy on his farm near the town of Catalo in Brazil.He monitors his fields on a daily basis so that he can react quickly to problems.You can read more in the Magazine section o

4、f this Annual Report beginning on page 9.Key Data million 20152016Change from 2015(%)Bayer Group Sales 46,08546,769+1.5EBITDA 1 9,57310,785+12.7EBITDA before special items 1 10,25611,302+10.2EBITDA margin before special items 1 22.3%24.2%EBIT 1 6,2417,042+12.8EBIT before special items 1 7,0608,130+1

5、5.2Income before income taxes 5,2365,887+12.4Net income(from continuing and discontinued operations)4,1104,531+10.2Earnings per share(from continuing and discontinued operations)()1 4.975.44+9.5Core earnings per share(from continuing operations)()1 6.827.32+7.3Net cash provided by operating activiti

6、es(from continuing and discontinued operations)6,8909,089+31.9Net financial debt 17,44911,778 32.5Capital expenditures 2,5112,578+2.7 Bayer AG Total dividend payment 2,0672,233+8.0Dividend per share()2.502.70+8.0 Innovation Research and development expenses 4,2744,666+9.2Ratio of R&D expenses to sal